310 related articles for article (PubMed ID: 21324723)
1. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
Chong Y; Yakushiji H; Ito Y; Kamimura T
Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
[TBL] [Abstract][Full Text] [Related]
2. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
Craig M; Cumpston AD; Hobbs GR; Devetten MP; Sarwari AR; Ericson SG
Bone Marrow Transplant; 2007 Apr; 39(8):477-82. PubMed ID: 17322937
[TBL] [Abstract][Full Text] [Related]
3. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
Cumpston A; Craig M; Hamadani M; Abraham J; Hobbs GR; Sarwari AR
Transpl Infect Dis; 2013 Apr; 15(2):142-9. PubMed ID: 23279656
[TBL] [Abstract][Full Text] [Related]
4. Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies.
Chong Y; Yakushiji H; Ito Y; Kamimura T
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e171-5. PubMed ID: 20471883
[TBL] [Abstract][Full Text] [Related]
5. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
[TBL] [Abstract][Full Text] [Related]
6. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
7. Gram-negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies.
Chee L; Brown M; Sasadeusz J; MacGregor L; Grigg AP
J Infect; 2008 Apr; 56(4):227-33. PubMed ID: 18342947
[TBL] [Abstract][Full Text] [Related]
8. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia.
Verlinden A; Jansens H; Goossens H; van de Velde AL; Schroyens WA; Berneman ZN; Gadisseur AP
Eur J Haematol; 2014 Oct; 93(4):302-8. PubMed ID: 24750350
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin prophylaxis in neutropenic patients.
von Baum H; Sigge A; Bommer M; Kern WV; Marre R; Döhner H; Kern P; Reuter S
J Antimicrob Chemother; 2006 Oct; 58(4):891-4. PubMed ID: 16880172
[TBL] [Abstract][Full Text] [Related]
10. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients.
Gudiol C; Bodro M; Simonetti A; Tubau F; González-Barca E; Cisnal M; Domingo-Domenech E; Jiménez L; Carratalà J
Clin Microbiol Infect; 2013 May; 19(5):474-9. PubMed ID: 22524597
[TBL] [Abstract][Full Text] [Related]
11. Bacteremia in patients with hematological malignancies.
Wang FD; Lin ML; Liu CY
Chemotherapy; 2005 May; 51(2-3):147-53. PubMed ID: 15886475
[TBL] [Abstract][Full Text] [Related]
12. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis.
Busca A; Cavecchia I; Locatelli F; D'Ardia S; De Rosa FG; Marmont F; Ciccone G; Baldi I; Serra R; Gaido E; Falda M
Transpl Infect Dis; 2012 Feb; 14(1):40-8. PubMed ID: 21599817
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002.
Kern WV; Steib-Bauert M; de With K; Reuter S; Bertz H; Frank U; von Baum H
J Antimicrob Chemother; 2005 Jan; 55(1):57-60. PubMed ID: 15574472
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies.
Kara Ö; Zarakolu P; Aşçioğlu S; Etgül S; Uz B; Büyükaşik Y; Akova M
Infect Dis (Lond); 2015; 47(10):686-93. PubMed ID: 26024284
[TBL] [Abstract][Full Text] [Related]
15. [Gram-negative bacteremia in neutropenic patients with hematologic disorders. Experiences with prophylactic use of fluoroquinolones].
Sinkó J; Cser V; Konkoly Thege M; Masszi T
Orv Hetil; 2011 Jul; 152(27):1063-7. PubMed ID: 21676672
[TBL] [Abstract][Full Text] [Related]
16. Emerging bacterial resistance patterns in febrile neutropenic patients: experience at a tertiary care hospital in Pakistan.
Khan MA; Siddiqui BK; Shamim A; Yosuf MA; Ahmed U; Zakiullah N; Burney IA
J Pak Med Assoc; 2004 Jul; 54(7):357-60. PubMed ID: 15449917
[TBL] [Abstract][Full Text] [Related]
17. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Baskaran ND; Gan GG; Adeeba K
Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
[TBL] [Abstract][Full Text] [Related]
18. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.
Cattaneo C; Quaresmini G; Casari S; Capucci MA; Micheletti M; Borlenghi E; Signorini L; Re A; Carosi G; Rossi G
J Antimicrob Chemother; 2008 Mar; 61(3):721-8. PubMed ID: 18218645
[TBL] [Abstract][Full Text] [Related]
19. Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres.
Castagnola E; Haupt R; Micozzi A; Caviglia I; Testi AM; Giona F; Parodi S; Girmenia C
Clin Microbiol Infect; 2005 Jun; 11(6):505-7. PubMed ID: 15882204
[TBL] [Abstract][Full Text] [Related]
20. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
Slobbe L; Waal Lv; Jongman LR; Lugtenburg PJ; Rijnders BJ
Eur J Cancer; 2009 Nov; 45(16):2810-7. PubMed ID: 19647995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
